Boehringer enrolls first patients in phase III study to evaluate dabigatran etexilate
Germany-based Boehringer Ingelheim has enrolled the first patients in its new RE-DUAL PCI international phase III study to evaluate dabigatran...
AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for companion diagnostic tests
AstraZeneca today announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next...
FDA plans to take steps to enhance the collection and availability of clinical trial data on demographic subgroups.
By: Margaret A. Hamburg, M.D.Margaret A. Hamburg, M.D., is Commissioner of the U.S. Food and Drug Administration August...
Astrazeneca and Mitsubishi Tanabe Pharma Corporation announce research collaboration in diabetic nephropathy
AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC) today announce a three-year research collaboration in the area of diabetic nephropathy. The...
AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients with complicated intra-abdominal infections (cIAI)
CAZ-AVI treated patients with cIAI as effectively as meropenem CAZ-AVI also treated cIAI patients infected with ceftazidime-resistant bacteria as...
FDA Grants Tentative Approval For Lilly And Boehringer Ingelheim’s Basaglar™ (Insulin Glargine Injection)
The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is indicated to...
ABBOTT JOINS FORCES WITH U.S. DEPARTMENT OF DEFENSE TO DEVELOP PORTABLE BLOOD TESTS FOR EVALUATING CONCUSSIONS
Abbott and the United States Department of Defense today announced a collaboration with the intent to develop portable blood tests...
EISAI Files Lenvatinib in Europe for People With Radioiodine-Refractory Thyroid Cancer
FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. MEDIA EMA accepts accelerated review for orphan therapy in hard-to-treat thyroid cancer Eisai...
Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a...
CannaVest Reports Second Quarter 2014 Financial Results
CannaVest Corp. - ("CannaVest" or the "Company") is reporting financial results for the quarter ending June 30, 2014. Logo -...
About Us
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.